teclistimab | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

80 results for “teclistimab”

Trials

View all 60 →

Limited-duration Teclistamab

75 participants · First posted Jul 6, 2023

Active, not recruiting

A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

194 participants · First posted Sep 21, 2020

Active, not recruiting

MMRC Horizon One: RRMM (MMRC-099)

300 participants · First posted Dec 15, 2023

Drugs

Investigational

Teclistamab(Tecvayli)

Conditions: Refractory Multiple Myeloma, Relapsed Multiple Myeloma

News

View all 19 →

J&J's TALVEY® Navigates Regulatory Hurdles for Multiple Myeloma Treatment

Optimizing Treatment Strategies for Relapsed Multiple Myeloma: From CAR T-Cell Therapy to Novel Combinations

Teclistamab Shows Promise in Heavily Pretreated Multiple Myeloma

Page 1 of 8